Faraj Nakhleh
Président chez EMERGIA INC.
Profil
Faraj M.
Nakhleh is currently the President & Chief Executive Officer at Trak Concepts, Inc. since 2008 and the Chairman at Emergia, Inc. since 2022.
Previously, he served as the Director at NTI Newmerical, Inc. and as a Director at Ambrilia Biopharma, Inc. from 2010 to 2011.
He also worked as a Partner at Raymond Chabot Grant Thornton LLP.
Mr. Nakhleh holds a graduate degree from McGill University and an undergraduate degree from Robert College.
Postes actifs de Faraj Nakhleh
| Sociétés | Poste | Début |
|---|---|---|
| EMERGIA INC. | Président | 16/04/2024 |
| Trak Concepts, Inc. | Directeur Général | 09/10/2009 |
Anciens postes connus de Faraj Nakhleh
| Sociétés | Poste | Fin |
|---|---|---|
Ambrilia Biopharma, Inc.
 Ambrilia Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Ambrilia Biopharma, Inc. discovers and develops novel treatments for viral diseases and cancer. Its product portfolio is comprised of oncology and antiviral assets, including two new formulations of existing peptides for cancer treatment, a targeted delivery technology for cancer, an HIV protease inhibitor program as well as HIV integrase and entry inhibitors, Hepatitis C virus inhibitors and anti-Influenza A compounds. The company was founded on November 27, 1986 and is headquartered in Montréal, Canada. | Directeur/Membre du Conseil | 08/04/2011 |
Raymond Chabot Grant Thornton LLP
 Raymond Chabot Grant Thornton LLP Miscellaneous Commercial ServicesCommercial Services Raymond Chabot Grant Thornton LLP engages in the provision of tax, recovery and organization, management consulting, financial advisory, digital and technology, assurance and human resource consulting services. It serves the tourism, leisure and culture, natural resources, mining and forestry, manufacturing, and retail and distribution industry. The company was founded in 1948 and is headquartered in Montreal, Canada. | Corporate Officer/Principal | - |
NTI Newmerical, Inc.
 NTI Newmerical, Inc. Packaged SoftwareTechnology Services NTI Newmerical, Inc. develops advanced CFD multi-disciplinary simulation software for the aeronautics, automotive, marine and power and process industries. It develops and provides in-flight icing simulation software and associated design, testing and certification services to aerospace companies desirous to apply safety standards that meet and exceed regulations. It was founded by Wagdi G. Habashi is headquartered in Montreal, Canada. | Directeur/Membre du Conseil | - |
Formation de Faraj Nakhleh
| Robert College | Undergraduate Degree |
| McGill University | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| EMERGIA INC. | Finance |
| Entreprise privées | 4 |
|---|---|
NTI Newmerical, Inc.
NTI Newmerical, Inc. Packaged SoftwareTechnology Services NTI Newmerical, Inc. develops advanced CFD multi-disciplinary simulation software for the aeronautics, automotive, marine and power and process industries. It develops and provides in-flight icing simulation software and associated design, testing and certification services to aerospace companies desirous to apply safety standards that meet and exceed regulations. It was founded by Wagdi G. Habashi is headquartered in Montreal, Canada. | Technology Services |
| Trak Concepts, Inc. | |
Raymond Chabot Grant Thornton LLP
Raymond Chabot Grant Thornton LLP Miscellaneous Commercial ServicesCommercial Services Raymond Chabot Grant Thornton LLP engages in the provision of tax, recovery and organization, management consulting, financial advisory, digital and technology, assurance and human resource consulting services. It serves the tourism, leisure and culture, natural resources, mining and forestry, manufacturing, and retail and distribution industry. The company was founded in 1948 and is headquartered in Montreal, Canada. | Commercial Services |
Ambrilia Biopharma, Inc.
Ambrilia Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Ambrilia Biopharma, Inc. discovers and develops novel treatments for viral diseases and cancer. Its product portfolio is comprised of oncology and antiviral assets, including two new formulations of existing peptides for cancer treatment, a targeted delivery technology for cancer, an HIV protease inhibitor program as well as HIV integrase and entry inhibitors, Hepatitis C virus inhibitors and anti-Influenza A compounds. The company was founded on November 27, 1986 and is headquartered in Montréal, Canada. | Health Technology |
